We present evidence that (i) TBXA2R is transcriptionally repressed by a BRCA1/c-Myc complex, (ii) components of the Rho/ROCK pathway may be important mediators of TBXA2R signalling in TNBCs, (iii) TBXA2R may have roles in controlling endogenous ROS levels and DNA damage and (iv) whilst this receptor is a biomarker of poor prognosis in breast cancer overall, it may possess potential to serve as a predictive marker of good outcomes to DNA damage therapies in TNBCs. This evidence concerns the gene MYC and breast cancer.